ASP Isotopes, Inc. (ASPI)
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-09-04
$4.20+7.69%
Close 2026-09-04 · 1-day change
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-09-04
QuarterlyIQ Insights · ASPI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Finish commissioning and ramp production of liquid helium and LNG at Virginia Gas Project to nameplate capacity in Q3 2026, then advance Phase 2 construction in 2H 2026.
Stated as a priority in 3 of last 3 quarters. The company completed Phase 1 drilling ahead of schedule and expects to produce approximately 2,500 GJ/day LNG and 70 Mcf/day liquid helium with commercial production commencing in Q3 2026. The ramp to nameplate capacity is targeted for 2H 2026, with Phase 2 construction to start thereafter. The trajectory is delivering as planned.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Materials names rated weak grew net income 48% of the time over the next year (vs 53% for the rest of the cohort, n=1946).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Phase 1 expected to produce 2,500 GJ/day LNG and 70 Mcf/day helium, commercial production in Q3 2026, ramp to nameplate capacity in 2H 2026.”
“Phase 1 nameplate capacity of 2,500 GJ/day LNG and 58 MCF/day helium expected in Q3 2026; Phase 2 construction to start after Phase 1.”
“Completed Phase 1 drilling ahead of schedule; expect to obtain helium Phase 1 nameplate capacity in Q3 2026.”
Expand PET Labs operations including US acquisitions to achieve targeted 2026 revenues of about $14 million, up from $6 million in 2025.
Stated as a priority in 2 of last 2 quarters. PET Labs revenue is forecast to grow from $6 million in 2025 to approximately $14 million in 2026, supported by operational progress and US acquisitions. The trajectory is on track to meet the growth target.
“Targets revenues of $10 million or more from radiopharmacies in 2026, approximately double 2025 revenue.”
“Acquired two US radiopharmacies; PET Labs operational progress with second cyclotron operational in 2025.”
Begin commercial shipments of enriched isotopes including Silicon-28, Carbon-14, and Ytterbium-176 during 2026 to expand product offerings.
Stated as a priority in 2 of last 2 quarters. The company shipped initial enriched isotope samples in 2025 and targets first commercial shipments of Yb-176 and Carbon-14 around mid to late 2026, with Si-28 shipments targeted in Q2 2026. The trajectory shows progress toward commercial shipments.
“Targeting initial commercial shipments of enriched Yb-176 around mid-year or Q3 2026; first enriched Si-28 product shipment targeted in Q2 2026.”
“Shipped first enriched Yb-176 sample in August 2025; shipped first enriched Si-28 samples in August 2025.”
Aim to achieve annual EBITDA exceeding $300 million by 2031 through growth in helium, LNG, isotope enrichment, and nuclear fuels businesses.
Stated as a priority in 2 of last 2 quarters. The company targets over $300 million EBITDA by 2031, with guidance indicating $50-100 million annual EBITDA in 2031. This is a long-term goal with progress dependent on execution; trajectory is mixed given current financial losses.
“Details behind greater than $300 million EBITDA target in 2031; singular focus in 2026 is execution.”
“Long-term EBITDA target greater than $300 million in 2031 stated.”
Progress Quantum Leap Energy's development and regulatory approvals toward a planned public listing.
Over the trailing year it converted 0.97x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
51 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Materials names rated volatile grew net income 52% of the time over the next year (vs 50% for the rest of the cohort, n=717).
Not investment advice. As of 2026-09-04.